

To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
LRRK2 D1994A/G2019S Mouse
Mouse Model
Transgenic mice overexpressing both a mutant form D1994A and G2019S of human LRRK2 directed by its endogenous promoter/enhancer regions on the BAC transgene.
Please note: Although founders were positively identified through genotyping and exhibited robust mRNA expression, these projects were halted due to a lack of any appreciable protein expression.
NOD2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in NOD2, including heterozygous and homozygous knockout, heterozygous, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
PINK1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PINK1, including heterozygous and homozygous P399L and A217D mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). *Heterozygous and homozygous L347P mutations are currently in development. Estimated Availability: Q1 2026.
PSMF1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PSMF1, including heterozygous and homozygous R242C and R231*, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
RAB32 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in RAB32, including heterozygous and homozygous S71R, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
SCARB2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SCARB2, including heterozygous and homozygous R424, heterozygous and homozygous W146Sfs*15, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
SMPD1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SMPD1, including heterozygous and homozygous L262Rfs*3, heterozygous and homozygous Q294K, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
TMEM175 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in TMEM175, including heterozygous and homozygous M393T mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). *Heterozygous and homozygous Q65P mutations are currently in development. Estimated Availability: Q1 2026.
VPS13C Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in VPS13C, including heterozygous and homozygous G1389R, heterozygous and homozygous R117*, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
LRRK2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in LRRK2, including heterozygous and homozygous N2081D, R1441G, I2020T, G2019S, and Y1699C mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP).*Heterozygous and homozygous R1398H and L1795F mutations are currently in development. Estimated Availability: Q1 2026.
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic